Noriyuki Kasahara, M.D., Ph.D.
Directorat4D Molecular Therapeutics· In the 2023 proxy
Noriyuki Kasahara, M.D., Ph.D. is Director of 4D Molecular Therapeutics.
Experience
- 4D Molecular TherapeuticsPublic company · 3 yr
- Director2023 – Present · 3 yrStock in role -36%
'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-2'%20d='M18.156,40.577.011,29.356l0-18.125L18.147,0'%20transform='translate(-0.004%20-0.001)'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-3'%20d='M35.133,14.327H26.354l4.389-7.163L35.127,0l4.395,7.164,4.389,7.163Z'%20transform='translate(-16.985)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-4'%20d='M51.052,93.782l0-8.211,18.178-3.019Z'%20transform='translate(-32.9%20-53.206)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-5'%20d='M69.213,11.223l-9.4,3.1L51.035,0Z'%20transform='translate(-32.892%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-6'%20d='M.01,11.23l9.387,3.1L18.148,0Z'%20transform='translate(-0.006%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-7'%20d='M75.741,34.672l9.4-3.1,0,18.125Z'%20transform='translate(-48.815%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-8'%20d='M9.406,34.672l-9.4-3.1,0,18.125Z'%20transform='translate(-0.004%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-9'%20d='M18.15,93.786l.016-8.209L0,82.56Z'%20transform='translate(0%20-53.21)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-10'%20d='M59.826,40.3,51.047,58.34l18.178-3.019Z'%20transform='translate(-32.9%20-25.974)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-11'%20d='M9.393,40.3l8.773,18.041L0,55.321Z'%20transform='translate(0%20-25.971)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-12'%20d='M35.174,40.3H26.418l4.367,9.019,4.4,9.027,4.373-9.027,4.389-9.02Z'%20transform='translate(-17.026%20-25.974)'%20fill='%238fd4e2'/%3e%3c/svg%3e)
Roles come from the proxy statements of each company.
Activity
No new filings about this person in the feed.
Two people shown as one, or a wrong number?